Resultados de Búsqueda por Autor

1

artículo

Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians

Publicado por
Baek, SY, Lee, KH, Kim, SB, Gomez, HL, Vidaurre, T, Park, YH, Ahn, HK, Kim, YS, Park, IH, Ahn, SG, Lee, J, Jeong, JH, Kim, S, Kim, HJ

Publicado 2023

Enlace

Background: Fertility is an important issue for young women with breast cancer, but studies about physicians’ knowledge, attitudes, and practices toward fertility preservation (FP) are largely based on Western populations and do not reflect recent international guidelines for FP. In this international study, we aimed to assess the knowledge, attitudes, and practices of physicians from South Korea, other Asian countries, and Latin America toward FP in young women with breast cancer, and identify the related barriers. Methods: The survey was conducted anonymously among physicians from South Korea, other Asian countries, and Latin America involved in breast cancer care between November 2020 and July 2021. Topics included knowledge, attitudes, and perceptions toward FP; practice behaviors; barriers; and participant demographics. We grouped related questions around two main themes—discuss...

2

artículo

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Publicado por
Sun, JM, Shen, L, Shah, MA, Enzinger, P, Adenis, A, Doi, T, Kojima, T, Metges, JP, Li, Z, Kim, SB, Cho, BC, Mansoor, W, Li, SH, Sunpaweravong, P, Maqueda, MA, Goekkurt, E, Hara, H, Antunes, L, Fountzilas, C, Tsuji, A, Castro-Oliden, V, Liu Q, Shah S, Bhagia P, Kato K, KEYNOTE-590 Investigators.

Publicado 2021

Enlace

Background: First-line therapy for advanced oesophageal cancer is currently limited to fluoropyrimidine plus platinum-based chemotherapy. We aimed to evaluate the antitumour activity of pembrolizumab plus chemotherapy versus chemotherapy alone as first-line treatment in advanced oesophageal cancer and Siewert type 1 gastro-oesophageal junction cancer. Methods: We did a randomised, placebo-controlled, double-blind, phase 3 study across 168 medical centres in 26 countries. Patients aged 18 years or older with previously untreated, histologically or cytologically confirmed, locally advanced, unresectable or metastatic oesophageal cancer or Siewert type 1 gastro-oesophageal junction cancer (regardless of PD-L1 status), measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1, and Eastern Cooperative Oncology Group performance status of 0-1, were randomly assigned (1:1)...

3

artículo

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Publicado por
Cardoso, F, Paluch-Shimon, S, Senkus, E, Curigliano, G, Aapro, MS, André, F, Barrios, CH, Bergh, J, Bhattacharyya, GS, Biganzoli, L, Boyle, F, Cardoso, MJ, Carey, LA, Cortés, J, El Saghir, NS, Elzayat, M, Eniu, A, Fallowfield, L, Francis, PA, Gelmon, K, Gligorov, J, Haidinger, R, Harbeck, N, Hu, X, Kaufman, B, Kaur, R, Kiely, BE, Kim, SB, Lin, NU, Mertz, SA, Neciosup, SO, ffersen, BV, Ohno, S, Pagani, O, Prat, A, Penault-Llorca, F, Rugo, HS, Sledge, GW, Thomssen, C, Vorobiof, DA, Wiseman ,T, Xu, B, Norton, L, Costa, A, Winer, EP

Publicado 2020

Enlace

This ESO-ESMO ABC 5 Clinical Practice Guideline provides key recommendations for managing advanced breast cancer patients. It provides updates on managing patients with all breast cancer subtypes, LABC, follow-up, palliative and supportive care. Updated diagnostic and treatment algorithms are also provided. All recommendations were compiled by a multidisciplinary group of international experts. Recommendations are based on available clinical evidence and the collective expert opinion of the authors.